Objective. The purpose of the study was to investigate the significanc
e of p53 expression for the prognosis in patients with ovarian granulo
sa cell tumors (GCT). Methods. The records of 30 patients operated on
for GCT at Tampere University Hospital, Finland, were reviewed. The me
an age at the time of the diagnosis was 55 years. Twenty-one of the tu
mors were of FIGO stage I, three were of stage II, three were of stage
III, and three were of stage IV. Paraffin-embedded tumor specimens we
re analyzed by immunohistochemistry for expression of mutated p53 prot
ein and by how cytometry. Results. Eleven tumors were positive for p53
and 19 were negative. The median crude survival of p53-negative patie
nts was 10 times that of p53-positive ones (210 months vs 21 months, P
= 0.037, log-rank test). The association between p53 immunoreactivity
and stage was statistically significant (P = 0.026 Pearson chi(2) tes
t), while there was no association between p53 expression and DNA ploi
dy or S-phase fraction. Conclusion. Although the results should be con
sidered as preliminary, expression of mutated p53 in ovarian granulosa
cell tumors seems to be associated with unfavorable prognosis. (C) 19
97 Academic Press.